

From the Boston Business Journal:

<http://www.bizjournals.com/boston/news/2017/04/20/celgene-to-expand-in-cambridge-taking-former.html>

Celgene to expand in Cambridge, taking former Amgen space

Apr 20, 2017, 2:35pm EDT

Celgene Corp. is expanding its presence in Cambridge, leasing about 40,000 square feet of additional space in the Alewife neighborhood that was previously occupied by **Amgen**.

Amgen Inc. (Nasdaq: AMGN) occupied the fifth floor of 200 Cambridge Park Drive between January 2015 and September 2016, when staff there moved to the company's newly-expanded office in Kendall Square, a spokeswoman for the California drugmaker said. The lease officially expires at the end of this year.

Celgene (Nasdaq: CELG), which already leases part of 200 Cambridge Park Drive, recently committed to some of Amgen's former space, a spokesman for the New Jersey pharma giant said.

In December 2015, King Street Properties sold the building to a fund managed by Morgan Stanley Real Estate Investing for \$165.5 million. In addition to Celgene, tenants include cancer drug developer Unum Therapeutics and Enumeral Biomedical Holdings (OTCBB:ENUM).

The news comes shortly after Amgen announced that it would transfer some employees at its headquarters in Thousand Oaks, California, to either Kendall Square or an office in San Francisco. Amgen did not specify how many of those employees will move to Cambridge.

Celgene has moved to expand its presence in Massachusetts in recent years by acquiring or partnering with a number of local biotechs. The company purchased Boston-based Acetylon Pharmaceuticals in December for an undisclosed sum, and bought Delinia, a startup focused on autoimmune disorders, in January for \$300 million.

Max Stendahl
Biotech Reporter
Boston Business Journal



WARREN PATTERSON
200 Cambridge Park Drive in Cambridge